Recombinant Litoria citropa Caerulein-2.2/2.2Y4

What is Recombinant Litoria citropa Caerulein-2.2/2.2Y4?

Recombinant Litoria citropa Caerulein-2.2/2.2Y4 is a synthetic version of a naturally occurring peptide found in the skin secretions of the Australian Blue Mountains tree frog (Litoria citropa). It belongs to a family of sixteen caerulein-type peptides isolated from this species, which are organized into four distinct groups. Caerulein-2.2/2.2Y4 specifically belongs to the second group of these peptides, characterized by structures similar to caerulein 2.1 [pEQDY(SO₃)TGAHMDF-NH₂] . The designation "2.2" indicates it's the second variant in Group 2, while "Y4" likely signifies a tyrosine substitution at position 4.

Caerulein peptides are known for their bioactive properties, with significant effects on pancreatic function and structural similarity to cholecystokinin (CCK), an important digestive hormone. As a recombinant protein, it is produced through genetic engineering techniques rather than isolated directly from frog skin secretions, enabling consistent production for research purposes. This approach eliminates variation in natural sources and provides a reliable supply for scientific investigation.

How does Caerulein-2.2/2.2Y4 differ from other caeruleins?

Caerulein-2.2/2.2Y4 differs from other caerulein peptides primarily in its amino acid sequence. The caerulein peptides from Litoria citropa are categorized into four main groups based on their structural variations:

• Group 1 (Caerulein 1.1): [pEQDY(SO₃)TGWMDF-NH₂]

• Group 2 (Caerulein 2.1): [pEQDY(SO₃)TGAHMDF-NH₂]

• Group 3 (Caerulein 3.1): [pEQDY(SO₃)GTGWMDF-NH₂]

• Group 4 (Caerulein 4.1): [pEQDY(SO₃)TGSHMDF-NH₂]

Each group contains multiple variants, with additional diversity created by modifications such as the replacement of methionine with phenylalanine and the presence of desulfated analogs. While specific information about Caerulein-2.2/2.2Y4 is not provided in the search results, as a member of Group 2, it would feature amino acid substitutions that distinguish it from the prototype Caerulein 2.1 structure.

These structural differences, though subtle, can significantly impact receptor binding affinity, biological activity, stability, and pharmacokinetic properties. Research on caerulein variants demonstrates that different peptides interact differently with CCK receptor subtypes, influencing their physiological effects . Understanding these differences is crucial for researchers designing experiments with specific caerulein variants.

What is the structural characterization of Caerulein-2.2/2.2Y4?

Structural characterization of Caerulein-2.2/2.2Y4 typically involves multiple analytical techniques to determine its precise composition and modifications. Based on analysis methods used for similar peptides, the characterization would include:

• Mass Spectrometry Analysis: Negative ion electrospray mass spectrometry (ES-MS) is commonly used to determine the molecular weights of caeruleins from their [M - H]⁻ ions. The sequences can be determined from the B and Y + 2 cleavage ions in the mass spectra of the [MH⁺ - SO₃]⁺ ions . This technique provides accurate mass measurements and sequence confirmation.

• Amino Acid Sequence Analysis: Based on the general pattern of Group 2 caerulein peptides, Caerulein-2.2/2.2Y4 would have a sequence similar to Caerulein 2.1 [pEQDY(SO₃)TGAHMDF-NH₂], potentially with a tyrosine substitution at position 4 . Complete sequencing would confirm the exact positions of amino acid substitutions.

• Post-translational Modifications: Key modifications include a sulfated tyrosine residue, which is critical for biological activity, a pyroglutamate at the N-terminus, and amidation at the C-terminus . These modifications significantly impact receptor binding and peptide stability.

• Purity Assessment: SDS-PAGE analysis typically confirms purity levels (>85% for commercial preparations) . Additional chromatographic methods may provide higher-resolution purity analysis.

• Secondary Structure Analysis: Techniques such as circular dichroism (CD) spectroscopy would analyze the peptide's conformation in solution, providing insights into its functional characteristics.

Understanding the complete structural profile is essential for interpreting biological activity data and ensuring experimental reproducibility when working with this peptide.

What methods are used to produce recombinant Caerulein-2.2/2.2Y4?

Recombinant Caerulein-2.2/2.2Y4 production involves sophisticated molecular biology and protein expression techniques. The typical production process includes:

• Gene Synthesis and Vector Construction: The DNA sequence encoding Caerulein-2.2/2.2Y4 is chemically synthesized based on the known amino acid sequence, with codon optimization for the chosen expression system. This synthetic gene is then cloned into an appropriate expression vector containing necessary regulatory elements.

• Expression System Selection: According to available data, a baculovirus expression system is commonly used for recombinant caerulein production . This system utilizes insect cells, which offer advantages for producing eukaryotic proteins with proper folding and post-translational modifications that are critical for caerulein functionality.

• Protein Expression Optimization: The recombinant vector is introduced into the insect cell expression host, which then produces the peptide. Culture conditions (temperature, pH, media composition) require optimization to maximize yield while maintaining proper post-translational modifications, particularly the crucial tyrosine sulfation.

• Purification Strategy: The expressed peptide undergoes purification using chromatographic techniques, potentially including affinity chromatography (if tagged), ion-exchange chromatography, and/or reversed-phase HPLC. These methods separate the target peptide from cellular components and potential contaminants.

• Quality Control Assessment: The final product undergoes rigorous quality control, typically achieving >85% purity by SDS-PAGE . Additional analysis by mass spectrometry confirms the correct molecular weight and modification status, while functional assays verify biological activity.

Understanding these production methods is essential for researchers to assess potential batch-to-batch variation and interpret experimental results appropriately when working with this recombinant peptide.

How is the purity of recombinant Caerulein-2.2/2.2Y4 assessed?

Assessing the purity of recombinant Caerulein-2.2/2.2Y4 requires multiple complementary analytical techniques to ensure both structural integrity and functional activity. Standard purity assessment methods include:

• SDS-PAGE Analysis: This fundamental technique separates proteins based on molecular weight. For high-purity peptide preparations, a single band should be visible at the expected molecular weight. Commercial preparations typically aim for >85% purity by SDS-PAGE . This method provides a basic visual confirmation of purity but may not detect subtle contaminants.

• High-Performance Liquid Chromatography (HPLC): Analytical HPLC, particularly reversed-phase HPLC, offers high-resolution separation of peptides and can detect impurities not visible by gel electrophoresis. Purity is calculated as the percentage of the target peak area relative to the total peak area, providing a quantitative measure of sample homogeneity.

• Mass Spectrometry Characterization: Mass spectrometry confirms both identity and purity of the peptide. Techniques like MALDI-TOF or ESI-MS can detect the exact molecular weight and identify potential contaminants or degradation products . This method is particularly valuable for detecting modifications or truncations that might not affect electrophoretic mobility.

• Functional Purity Assessment: Bioactivity assays, such as receptor binding or cellular response measurements, evaluate functional purity by confirming the peptide exhibits the expected biological activity. This approach addresses the crucial question of whether structural purity translates to functional activity.

For research applications requiring high reproducibility, multiple purity assessments should be conducted rather than relying on a single method. This comprehensive approach ensures both structural and functional integrity of the recombinant peptide.

What expression systems are optimal for producing this peptide?

Several expression systems can be employed for producing recombinant Caerulein-2.2/2.2Y4, each with distinct advantages and limitations that affect yield, post-translational modifications, and biological activity:

• Baculovirus-Insect Cell System: According to available data, this is a commonly used system for caerulein peptides . This system offers significant advantages including:

  • Capacity for eukaryotic post-translational modifications, particularly tyrosine sulfation

  • Efficient secretion of small peptides into culture medium

  • Ability to handle complex disulfide bond formation when present

  • Lower risk of endotoxin contamination compared to bacterial systems

• Yeast Expression Systems (S. cerevisiae or P. pastoris):

  • Combine advantages of microbial growth with some eukaryotic post-translational capabilities

  • Provide good secretion efficiency for small peptides

  • Can perform sulfation of tyrosine residues, which is critical for caerulein activity

  • Offer balanced cost-effectiveness and modification capability

• Mammalian Cell Expression Systems:

  • Provide the most authentic post-translational modifications

  • May be necessary if specific modifications like sulfation are critical to function

  • Generally yield lower quantities at higher cost than other systems

  • Most suitable when absolute fidelity to native structure is required

• Bacterial Expression Systems:

  • While high-yielding and cost-effective, these systems generally lack the ability to perform key post-translational modifications like tyrosine sulfation

  • May require additional in vitro modification steps to generate fully active peptides

  • Better suited for producing desulfated analogs for comparative studies

For Caerulein-2.2/2.2Y4, which contains a sulfated tyrosine residue crucial for its biological activity, expression systems capable of this post-translational modification (baculovirus-insect cell, yeast, or mammalian systems) would be preferable over bacterial systems that lack this capability . The choice depends on specific requirements for yield, purity, modifications, and cost considerations.

What are the optimal storage conditions for Recombinant Caerulein-2.2/2.2Y4?

Proper storage is critical for maintaining the structural integrity and biological activity of Recombinant Caerulein-2.2/2.2Y4. Based on information from similar caerulein peptides, the recommended storage conditions are:

• Temperature Requirements:

  • For routine use: Store at -20°C

  • For extended storage: Conserve at -20°C or preferably -80°C to minimize degradation

  • Working aliquots can be maintained at 4°C for up to one week

• Storage Forms and Stability:

  • Lyophilized (freeze-dried) form offers greater stability, with a typical shelf life of 12 months at -20°C

  • In liquid form, stability decreases to approximately 6 months at -20°C/-80°C

  • Stability is significantly affected by buffer composition, pH, and presence of stabilizers

• Stabilization Strategies:

  • Addition of glycerol (typically 5-50% final concentration) helps maintain stability during freeze-thaw cycles

  • Commercial suppliers often recommend 50% glycerol for long-term storage at -20°C/-80°C

  • Alternative stabilizers include trehalose or albumin at appropriate concentrations

• Aliquoting Recommendations:

  • Prepare small working aliquots to avoid repeated freeze-thaw cycles, which can degrade the peptide

  • Use sterile, low-protein binding tubes for storage

  • Document preparation date and storage conditions for each aliquot

• Additional Precautions:

  • Protect from light, especially if reconstituted in solution, as some amino acids (particularly tryptophan, tyrosine, and phenylalanine) are photosensitive

  • Avoid exposure to oxidizing agents that could affect methionine residues

  • Minimize exposure to extreme pH conditions that may affect stability

Implementing these storage protocols ensures maximum retention of structural integrity and biological activity, particularly for the sensitive post-translational modifications that are crucial for caerulein function.

How should Recombinant Caerulein-2.2/2.2Y4 be reconstituted for experiments?

Proper reconstitution of Recombinant Caerulein-2.2/2.2Y4 is crucial for maintaining its biological activity in experimental settings. The recommended protocol includes:

• Pre-Reconstitution Preparation:

  • Briefly centrifuge the vial containing lyophilized peptide to bring contents to the bottom before opening

  • Allow the vial to reach room temperature before reconstitution to prevent condensation, which could affect peptide stability

  • Use appropriate personal protective equipment and aseptic technique

• Reconstitution Solution Selection:

  • Use deionized sterile water as the primary reconstitution solution

  • The recommended concentration range is 0.1-1.0 mg/mL

  • For specific applications, consider phosphate-buffered saline (PBS) or other physiological buffers at neutral pH

• Reconstitution Procedure:

  • Add the reconstitution solution slowly to the vial containing the lyophilized peptide

  • Gently rotate or swirl rather than vortexing, as aggressive mixing can cause degradation

  • Allow the solution to sit for 5-10 minutes at room temperature, then mix gently until completely dissolved

• Post-Reconstitution Processing:

  • For long-term storage of reconstituted peptide, add glycerol to a final concentration of 5-50%

  • Commercial suppliers often recommend 50% glycerol for optimal stability

  • Prepare small working aliquots to avoid repeated freeze-thaw cycles

  • Use sterile techniques throughout to prevent microbial contamination

• Application-Specific Considerations:

  • For cell culture experiments, ensure the reconstitution solution and final peptide preparation are sterile

  • Filter sterilization can be performed using a 0.22 μm filter, though some peptide loss may occur

  • For receptor binding assays, consider using buffers containing protease inhibitors to prevent degradation

Following these reconstitution guidelines ensures the peptide maintains its native structure and biological activity, which is essential for obtaining reliable and reproducible experimental results.

What is the shelf life of Recombinant Caerulein-2.2/2.2Y4 under different storage conditions?

The shelf life of Recombinant Caerulein-2.2/2.2Y4 varies considerably depending on its form, storage conditions, and handling procedures. Based on information from similar peptides, the expected stability profiles are:

• Lyophilized Form Stability:

  • At -20°C: Approximately 12 months

  • At -80°C: Potentially longer than 12 months, though specific stability studies would be needed to confirm

  • Room temperature: Limited stability; not recommended for storage beyond a few hours during experimental procedures

• Liquid Form Stability:

  • At -20°C/-80°C: Approximately 6 months

  • At 4°C (working aliquots): Up to one week

  • At room temperature: Limited to hours; should be kept on ice during experiments

• Stability-Influencing Factors:

  • Storage temperature: Lower temperatures generally provide longer stability

  • Buffer composition: Certain buffer components may enhance or reduce stability

  • Presence of glycerol: Addition of glycerol (5-50%) can extend shelf life significantly

  • Exposure to freeze-thaw cycles: Each cycle reduces stability; should be minimized

  • Initial purity: Higher purity preparations typically have longer shelf lives

• Degradation Indicators:

  • Solution becomes cloudy or contains visible precipitates

  • Loss of biological activity in functional assays

  • Appearance of additional bands/peaks in analytical tests

  • Changes in mass spectrometry profile, particularly loss of post-translational modifications

• Best Practices for Maximum Shelf Life:

  • Store lyophilized peptide at -80°C when possible

  • Prepare small aliquots after reconstitution to minimize freeze-thaw cycles

  • Include stabilizers like glycerol for reconstituted peptides

  • Maintain detailed records of production date, reconstitution date, and observed activity

Regular quality control testing is recommended for critical applications, especially when using peptides that have been stored for extended periods. For the most sensitive applications, verification of biological activity prior to use is advisable regardless of storage duration.

What are the common research applications for Caerulein-2.2/2.2Y4?

Recombinant Caerulein-2.2/2.2Y4 has diverse applications in biomedical research, particularly in studies related to pancreatic function, receptor biology, and comparative biochemistry. Key research applications include:

• Pancreatic Physiology and Pathophysiology Studies:

  • Investigation of pancreatic secretion mechanisms

  • Research on pancreatic blood flow regulation, leveraging caerulein's ability to increase pancreatic blood flow by approximately 26% and vascular conductance by 24% at submaximal doses

  • Development of experimental pancreatitis models, as caeruleins at supramaximal doses can induce acute pancreatitis in research animals

  • Exploration of pancreatic tissue response to CCK receptor activation

• Receptor Biology and Signaling Research:

  • Investigation of cholecystokinin (CCK) receptor subtypes and their differential functions

  • Studies on signal transduction pathways initiated by CCK receptor activation

  • Research on the distinct roles of CCK1 and CCK2 receptors, as caerulein's vascular effects are mediated by CCK2 receptors while exocrine effects require CCK1 receptors

  • Structure-activity relationship studies comparing different caerulein variants

• Vascular Function Investigations:

  • Studies on microcirculation in the pancreas and potentially other organs

  • Research on vascular conductance changes in response to receptor activation

  • Investigation of the 109% increase in vascular conductance observed during caerulein-induced pancreatitis

  • Exploration of vascular effects in both normal and disease states

• Comparative Biochemistry and Evolutionary Studies:

  • Analysis of the relationship between amphibian defensive peptides and mammalian digestive hormones

  • Comparative studies of caerulein variants across different amphibian species

  • Investigation of the sixteen distinct caerulein-type peptides identified in Litoria citropa

  • Research on post-translational modifications in naturally occurring peptides

• Analytical Method Development:

  • Refinement of mass spectrometry techniques for peptide characterization

  • Development of immunoassays for detection of caerulein peptides

  • Validation of detection methods for naturally occurring peptides in biological samples

These applications leverage the unique properties of caerulein peptides, including their structural diversity, receptor interactions, and biological activities in various systems.

How does Caerulein-2.2/2.2Y4 interact with CCK receptors compared to other caeruleins?

The interaction between Caerulein-2.2/2.2Y4 and CCK receptors involves complex pharmacological mechanisms that differ from other caerulein variants. While specific data on Caerulein-2.2/2.2Y4 is not provided in the search results, insights can be drawn from research on related caerulein peptides:

• CCK Receptor Subtype Selectivity:

  • Caerulein peptides interact with two main cholecystokinin receptor subtypes: CCK1 (formerly CCKA) and CCK2 (formerly CCKB)

  • Research demonstrates distinct physiological effects mediated through each receptor type: caerulein increases pancreatic blood flow via CCK2 receptors, while exocrine effects (amylase output) are mediated through CCK1 receptors

  • The specific amino acid sequence of Caerulein-2.2/2.2Y4 would influence its relative affinity for CCK1 versus CCK2 receptors

• Structure-Activity Relationship Determinants:

  • The sulfated tyrosine residue [Y(SO₃)] is critical for high-affinity binding to CCK receptors

  • The C-terminal region influences receptor activation efficacy

  • Amino acid substitutions in the central region (where Caerulein-2.2/2.2Y4 differs from other variants) affect receptor subtype selectivity

  • All sixteen caerulein peptides from Litoria citropa share common structural elements but differ in specific amino acid positions

• Pharmacological Evidence from Related Peptides:

  • The vascular effects of caerulein are abolished by CCK2 antagonists while CCK1 antagonists remain inactive

  • Conversely, amylase output stimulated by caerulein is blocked by CCK1 receptor antagonists but not by CCK2 receptor inhibitors

  • These differential effects demonstrate the complex interaction profile of caerulein peptides with CCK receptor subtypes

• Receptor Activation Mechanisms:

  • Caerulein binding to CCK2 receptors increases pancreatic blood flow by 26% and vascular conductance by 24%

  • During caerulein-induced pancreatitis, vascular conductance increases by 109% and remains elevated, while vascular flow initially increases by 62% before returning to baseline

  • The CCK2 agonist gastrin-17 mimics caerulein's vascular effects, further confirming the role of this receptor subtype

Understanding these receptor interaction mechanisms is essential for designing experiments that target specific physiological processes and for interpreting results in the context of CCK receptor biology.

What dosages are appropriate for in vitro vs. in vivo experiments?

Appropriate dosing of Recombinant Caerulein-2.2/2.2Y4 varies significantly between in vitro and in vivo experimental protocols. Based on research with related caerulein peptides, the following dosage guidelines are recommended:

In Vitro Experimental Dosing:

• Cell-Based Functional Assays:

  • For submaximal stimulation: 0.1-10 nM

  • For maximal stimulation: 10-100 nM

  • Dose-response curves should be generated to determine optimal concentration for specific cell types and endpoints

  • Include both CCK1 and CCK2 receptor antagonists in parallel experiments to distinguish receptor subtype involvement

• Receptor Binding Studies:

  • Concentration range: 0.1 nM to 1 μM

  • Initial broad range characterization followed by focused testing around the IC₅₀/EC₅₀ values

  • Include positive controls (native CCK) for comparison of binding kinetics and affinity

• Tissue Explant Experiments:

  • Lower range: 0.1-1 nM for physiological effects

  • Higher range: 10-100 nM for maximal stimulation

  • Exposure duration should be optimized for specific tissue types and endpoints

In Vivo Experimental Dosing:

• Submaximal Stimulation (for physiological response studies):

  • 0.4 nmol/kg/h via intravenous infusion for submaximal stimulation

  • This dosing produces a 26% increase in pancreatic blood flow and 24% increase in vascular conductance

  • Appropriate for studies investigating normal physiological responses

• Supramaximal Stimulation (for experimental pancreatitis induction):

  • 3 × 25 nmol/kg via intraperitoneal injection induces acute pancreatitis

  • This dosing causes significant increases in vascular conductance (109%) and initial vascular flow (62%)

  • Suitable for pathophysiological models and disease mechanism studies

• Administration Route Considerations:

  • Intravenous administration provides controlled delivery and is optimal for pharmacokinetic studies

  • Intraperitoneal injection is commonly used for experimental pancreatitis models

  • Subcutaneous administration may be appropriate for longer-duration studies

• Species-Specific Adjustments:

  • Dosages established in rat models may require adjustment for other species

  • Smaller species (mice) generally require higher mg/kg doses due to metabolic scaling

  • Larger species may need lower mg/kg doses to achieve equivalent effects

These dosage recommendations should serve as starting points, with optimization required for specific experimental systems and objectives. Careful dose-finding studies are recommended when working with new experimental models or when investigating novel endpoints.

How can I validate the biological activity of Recombinant Caerulein-2.2/2.2Y4?

Validating the biological activity of Recombinant Caerulein-2.2/2.2Y4 requires a multi-faceted approach combining molecular, cellular, and physiological techniques. A comprehensive validation strategy includes:

• Receptor Binding Characterization:

  • Competitive binding assays using radiolabeled CCK or caerulein to determine binding affinity

  • Scatchard analysis to calculate dissociation constants (Kd values)

  • Displacement studies with CCK1- and CCK2-selective antagonists to determine receptor subtype specificity

  • Comparison with reference standards (native CCK or well-characterized caerulein variants)

• Cell-Based Functional Assays:

  • Intracellular calcium mobilization assays using fluorescent calcium indicators

  • Measurement of phospholipase C activation and inositol phosphate production

  • Assessment of amylase secretion from pancreatic acinar cells, which is mediated by CCK1 receptors

  • ERK/MAPK phosphorylation analysis via Western blot or ELISA as a downstream signaling marker

• Pancreatic Function Evaluation:

  • Ex vivo pancreatic tissue preparations to measure secretory responses

  • Assessment of amylase output, which is abolished by CCK1 receptor blockade but not by inhibition of CCK2 receptors

  • Perfused pancreas preparations to assess changes in vascular parameters

  • Measurement of pancreatic blood flow, which increases by 26% at submaximal caerulein doses

• In Vivo Validation Approaches:

  • Pancreatic blood flow measurements using hydrogen clearance method as described in published protocols

  • Assessment of vascular conductance changes, which increase by 24% with low caerulein doses

  • Evaluation of pancreatitis induction at supramaximal doses, manifested by a 109% increase in vascular conductance

  • Use of CCK1 and CCK2 receptor antagonists to confirm the receptor-specific nature of observed effects

• Comparative Profiling:

  • Side-by-side comparison with established caerulein standards

  • Parallel testing with the CCK2 agonist gastrin-17, which mimics caerulein's vascular effects

  • Dose-response curve generation to determine EC₅₀/ED₅₀ values compared to reference standards

This comprehensive validation approach ensures that the recombinant peptide exhibits the expected pharmacological profile and biological activities, essential for reliable interpretation of experimental results.

What are potential cross-reactivity concerns when working with this peptide?

When conducting research with Recombinant Caerulein-2.2/2.2Y4, several potential cross-reactivity issues should be considered to ensure experimental specificity and accurate interpretation of results:

• Receptor Cross-Reactivity Considerations:

  • CCK1 vs. CCK2 receptor selectivity may not be absolute, particularly at higher concentrations

  • Differential effects on biological processes occur through distinct receptor subtypes: vascular effects via CCK2 receptors and exocrine effects via CCK1 receptors

  • Possible interaction with gastrin receptors due to structural similarities between CCK and gastrin peptides

  • Potential low-affinity binding to other G-protein coupled receptors with similar binding pocket structures

• Cross-Reactivity Among Caerulein Variants:

  • Litoria citropa produces sixteen different caerulein-type peptides organized into four groups

  • Each group contains peptides with methionine or phenylalanine substitutions, along with sulfated and desulfated variants

  • Experiments designed to distinguish effects of specific variants require careful controls

  • Mass spectrometry methods should be optimized to distinguish between similar caerulein peptides

• Analytical Method Considerations:

  • Negative ion electrospray mass spectrometry (ES-MS) is used to determine molecular weights of caeruleins from their [M - H]⁻ ions

  • Peptide sequences can be determined from B and Y + 2 cleavage ions in the mass spectra of [MH⁺ - SO₃]⁺ ions

  • These analytical approaches help differentiate between closely related peptide variants

• Experimental Design Strategies to Address Cross-Reactivity:

  • Use receptor-specific antagonists to confirm mechanisms of action

  • Include CCK1 antagonists (which block amylase output) and CCK2 antagonists (which prevent vascular effects) in parallel experiments

  • Employ dose-response studies to identify concentration-dependent selectivity changes

  • Consider potential receptor desensitization during prolonged or repeated exposure

• Verification Approaches:

  • Confirm effects using knockout/knockdown models where available

  • Compare results with those obtained using more selective CCK1 or CCK2 agonists

  • Include appropriate negative controls to account for non-specific effects

  • Validate antibody specificity when using immunological detection methods

Understanding and addressing these cross-reactivity concerns is essential for designing controlled experiments and correctly interpreting research findings when working with Recombinant Caerulein-2.2/2.2Y4.

How does the post-translational modification status affect function?

Post-translational modifications (PTMs) significantly impact the structure, function, and biological activity of caerulein peptides. For Caerulein-2.2/2.2Y4, the following PTM considerations are critical for research applications:

• Tyrosine Sulfation Significance:

  • The sulfated tyrosine residue [Y(SO₃)] is a defining feature of caerulein peptides, as evident in all four groups of caerulein-type peptides from Litoria citropa

  • This modification dramatically enhances binding affinity to CCK receptors

  • Natural populations of caerulein peptides include both sulfated and desulfated analogs

  • Loss of sulfation can reduce receptor affinity by 100-1000 fold, significantly altering biological activity

• N-terminal Pyroglutamate Formation:

  • Caeruleins typically contain a pyroglutamate (pE) at the N-terminus, as indicated by "pE" in the sequences reported in the literature

  • This cyclization protects the peptide from aminopeptidase degradation, enhancing stability in biological fluids

  • Recombinant production systems must support this cyclization reaction for full biological activity

  • Absence of this modification could lead to rapid N-terminal degradation and reduced half-life

• C-terminal Amidation Impact:

  • The C-terminal amide group (-NH₂) present in caerulein sequences is important for receptor recognition

  • This modification affects the peptide's three-dimensional structure and receptor binding properties

  • Expression systems must have the necessary enzymatic machinery (peptidylglycine α-amidating monooxygenase) for this modification

  • Non-amidated variants typically show reduced binding affinity and altered signaling profiles

• Production System Considerations:

  • Baculovirus expression systems (used for similar caerulein peptides ) can perform many eukaryotic PTMs

  • Proper PTM verification by mass spectrometry is essential after production

  • Different expression systems have varying capacities for performing specific modifications

  • The quality of post-translational modifications directly affects functional outcomes in experimental settings

• Experimental Implications:

  • Researchers should verify the modification status of recombinant peptides before use

  • Comparative studies with modified and unmodified variants can reveal the contribution of specific PTMs

  • Storage conditions can affect modification stability, particularly sulfation, which may be lost under acidic conditions

  • Biological activity assays may show dramatically different results depending on modification status

The correct post-translational modification pattern, particularly tyrosine sulfation, N-terminal pyroglutamate formation, and C-terminal amidation, is essential for the full biological activity of Recombinant Caerulein-2.2/2.2Y4. Experimental design should account for these factors, and modification status should be regularly verified.